Xenon制药 XENE 深 沪
已收盘 08-01 16:00:00 美东时间
30.50
-0.040
-0.13%
华盛通- 最 高30.74
- 今 开30.29
- 成交量 75.42万股
- 最 低 30.00
- 昨 收 30.54
- 总市值 23.40亿
- 52周最高 46.00
- 市盈率 静 --
- 换手率 0.98%
- 52周最低 26.74
- 委 比 46.78%
- 总股本 7673.36万
- 历史最高 50.99
- 量 比 0.82
- 振 幅 2.42%
- 历史最低 2.10
- 每 手 1
- 风险率 4.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees
An announcement from Xenon ( ($XENE) ) is now available. Xenon Pharmaceuticals ...
08-02 05:42
Xenon Appoints CEO Ian Mortimer as Interim CFO
Xenon ( ($XENE) ) has issued an announcement. On June 30, 2025, Xenon Pharmaceu...
07-04 05:51
Xenon joins Russell 3000 and Russell 2000 indexes
Xenon Pharmaceuticals (NASDAQ:XENE) on Friday said the company has been added to the broad-market Russell 3000 and small-cap Russell 2000 Indexes as part of the annual reconstitution, effective at the...
06-28 04:09
Xenon Joins the Russell 3000® and Russell 2000® Indexes
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) has been added to the Russell 3000® and Russell 2000® Indexes. The Russell indexes track U.S. stocks by market capitalization and are widely used by investors. Xenon is a neuroscience-focused company advancing treatments for epilepsy and depression.
06-27 20:01
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
Xenon Pharmaceuticals Inc. has appointed Darren Cline as Chief Commercial Officer to lead the commercialization of azetukalner, a Phase 3 candidate for epilepsy, major depressive disorder, and bipolar depression. Cline, with over 30 years of experience in biopharmaceutical commercialization, will oversee the company's transition to a commercial-stage entity. His appointment follows the expected Phase 3 data for azetukalner in early 2026, aiming f...
06-24 12:30
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Xenon Pharmaceuticals Inc. will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL, from June 9-11, 2025. Ian Mortimer, President and CEO, will deliver a Fireside Chat on June 10, 2025, from 3:20 to 3:55 PM Eastern Time. A live audio webcast will be available on Xenon's website's Investors section, with a replay following the event.
06-03 20:01
Xenon Pharmaceuticals Announces Equity Inducement Grants for New Employees
An update from Xenon ( ($XENE) ) is now available. Xenon Pharmaceuticals announ...
05-31 04:47
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
梵高菲尼克斯制药公司向七名新员工授予了总计53,550股股票期权，行使价为每股$29.04，归属期为四年，有效期至十年。
05-30 20:01
Evercore ISI Group Initiates Coverage On Xenon Pharmaceuticals with Outperform Rating, Announces Price Target of $55
Evercore ISI Group analyst Cory Kasimov initiates coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform rating and announces Price Target of $55.
05-14 23:51
